Abstract

RECENT ADVANCES IN THE MANAGEMENT OF INFLAMMATORY BOWEL DISEASE

Atika Siddiqua, Ayesha Ambereen, Husna Saqlain,
Amreen Fahmina Siddiqua, Syeda Shiza Aleem and *Dr. S.P. Srinivas Nayak

ABSTRACT

Medical treatment for inflammatory bowel disease (IBD) has progressed significantly over the past decade to achieve and maintain clinical remission in patients & to overcome the side effects of existing drugs for IBD. Conventional therapy for IBD include the use of Amino salicylates, corticosteroids & Anti-microbials. Patients who fail to respond to the conventional therapy are treated with agents such as Calcineurin inhibitor (Cyclosporine), and Biologics like TNF-α inhibitors (Infliximab or Adalimumab) or Anti-cell adhesion molecules (Vedolizumab, natalizumab). These agents are targeted against pro-inflammatory cytokines such as Tumor Necrosis Factor-α (TNF-α), Interleukin-2 (IL-2) and Cell Surface Adhesion Molecules Integrin α4β7. In this review, we provide an overview on the recent advances in the treatment for IBD such as newer Biologics, Small Molecule drugs and Biosimilars effective for IBD and the role of other therapies like Probiotics, Prebiotics, Stem cell transplant and Faecal microbiota transplant and Microbiome targeting diet in the management of IBD.

Keywords: Inflammatory Bowel Disease, Crohn‘s Disease, Ulcerative Colitis, Biologics, Biosimilars, Stem cell transplantation.